Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.32 |
| ▸ | LOX | P28300 | 1/20 | 0.30 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10336471 | 0.74 | NAPRT (0.41) | — | |
| SCHEMBL969061 | 0.72 | ENPP2 (0.37) | ENPP2PTGS2LOXLOXL2 | |
| SCHEMBL12656068 | 0.70 | ENPP2 (0.39) | ENPP2PTGS2 | |
| SCHEMBL2179000 | 0.70 | PIK3CA (0.33) | ENPP2PTGS2 | |
| SCHEMBL2179886 | 0.70 | ENPP2 (0.31) | ENPP2PTGS2 | |
| SCHEMBL2176609 | 0.69 | PTGS2 (0.33) | ENPP2PTGS2 | |
| SCHEMBL2178152 | 0.69 | PTGS2 (0.34) | PTGS2 | |
| SCHEMBL20554194 | 0.69 | PTGS2 (0.31) | ENPP2PTGS2 | |
| SCHEMBL20554278 | 0.69 | PTGS2 (0.31) | ENPP2PTGS2 | |
| SCHEMBL1641567 | 0.68 | ENPP2 (0.37) | ENPP2PTGS2LOXLOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2375898-B1 | NOVEL HERBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2015-09-16 | — | — | EP | claimed |
| US-9045468-B2 | 2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin | ALBANY MOLECULAR RESEARCH, INC. (US) | 2015-06-02 | — | — | US | claimed |
| EP-2606049-A2 | 2,5-METHANO-AND 2,5-ETHANO-TETRAHYDROBENZAZEPINE DERIVATIVES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | Albany Molecular Research, Inc. (US) | 2013-06-26 | — | — | EP | claimed |
| WO-2013055910-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2013-04-18 | — | — | WO | claimed |
| US-20120046271-A1 | 2,5-Methano- and 2,5-Ethano-Tetrahydrobenzazepine Derivatives And Use Thereof To Block Reuptake Of Norepinephrine, Dopamine, and Serotonin | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-23 | — | — | US | claimed |
| WO-2012024397-A2 | 2,5-METHANO-AND 2,5-ETHANO-TETRAHYDROBENZAZEPINE DERIVATIVES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-02-23 | — | — | WO | claimed |
| US-20160235858-A1 | LIGAND-THERAPEUTIC AGENT CONJUGATES, SILICON-BASED LINKERS, AND METHODS FOR MAKING AND USING THEM | ALBANY MOLECULAR RES INC (US) | 2016-08-18 | — | — | US | disclosed |
| US-9352049-B2 | Ligand-therapeutic agent conjugates, silicon-based linkers, and methods for making and using them | ALBANY MOLECULAR RESEARCH, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| EP-2997824-A1 | NOVEL HERBICIDES | Syngenta Participations AG. (CH) | 2016-03-23 | — | — | EP | disclosed |
| EP-2968599-A1 | LIGAND-THERAPEUTIC AGENT CONJUGATES AND SILICON-BASED LINKERS | Albany Molecular Research, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2375898-B1 | NOVEL HERBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2015-09-16 | — | — | EP | disclosed |
| US-9045468-B2 | 2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin | ALBANY MOLECULAR RESEARCH, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| CN-104193693-A | NOVEL HERBICIDES | SYNGENTA LTD | 2014-12-10 | — | — | CN | disclosed |
| WO-2013055910-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2013-04-18 | — | — | WO | disclosed |
| US-20120046271-A1 | 2,5-Methano- and 2,5-Ethano-Tetrahydrobenzazepine Derivatives And Use Thereof To Block Reuptake Of Norepinephrine, Dopamine, and Serotonin | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-23 | — | — | US | disclosed |
| WO-2012024397-A2 | 2,5-METHANO-AND 2,5-ETHANO-TETRAHYDROBENZAZEPINE DERIVATIVES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-02-23 | — | — | WO | disclosed |
| US-6962923-B2 | Pyrazole compositions | PFIZER INC. (US) | 2005-11-08 | — | — | US | disclosed |
| US-20030232848-A1 | Pyrazole compositions | PFIZER INC. | 2003-12-18 | — | — | US | disclosed |
| US-6573270-B1 | Endothelin receptor antagonists | PFIZER INC. | 2003-06-03 | — | — | US | disclosed |
| EP-1072597-A1 | Pyrazoles and their use as endothelin antagonists | Pfizer Limited (GB) | 2001-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046271-A1 | 2,5-Methano- and 2,5-Ethano-Tetrahydrobenzazepine Derivatives And Use Thereof To Block Reuptake Of Norepinephrine, Dopamine, and Serotonin | HTR2B, HTR1B, HTR5A | ENPP2 3247/4885PTGS2 1665/4885LOX 3540/4885 |
| US-20030232848-A1 | Pyrazole compositions | EDNRB, EDNRA, AGTR1 | ENPP2 2223/4885PTGS2 698/4885LOX 2674/4885 |
| US-20160235858-A1 | LIGAND-THERAPEUTIC AGENT CONJUGATES, SILICON-BASED LINKERS, AND METHODS FOR MAKING AND USING THEM | CD44, CD47, SELPLG | ENPP2 425/4885PTGS2 4195/4885LOX 734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.